Cochrane Database of Systematic Reviews 2012
DOI: 10.1002/14651858.cd003881.pub3
|View full text |Cite
|
Sign up to set email alerts
|

Urethral injection therapy for urinary incontinence in women

Abstract: The available evidence base remains insufficient to guide practice. In addition, the finding that placebo saline injection was followed by a similar symptomatic improvement to bulking agent injection raises questions about the mechanism of any beneficial effects. One small trial comparing silicone particles with pelvic floor muscle training was suggestive of benefit at three months but it is not known if this was sustained, and the treatment was associated with high levels of postoperative retention and dysuri… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
128
0
9

Year Published

2012
2012
2020
2020

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 214 publications
(137 citation statements)
references
References 36 publications
0
128
0
9
Order By: Relevance
“…An updated Cochrane review in 2012 found insufficient data to allow for meta-analysis or support clinical decisionmaking. 8 Bulking agents have been demonstrated to be more effective than pelvic floor muscle therapy, but less effective than surgical management for SUI. Gluteraldehyde crosslinked bovine collagen (Contigen™) has often been used as an established comparison agent in clinical trials of novel bulking agents, but was removed from the market in 2010.…”
Section: Efficacymentioning
confidence: 99%
See 1 more Smart Citation
“…An updated Cochrane review in 2012 found insufficient data to allow for meta-analysis or support clinical decisionmaking. 8 Bulking agents have been demonstrated to be more effective than pelvic floor muscle therapy, but less effective than surgical management for SUI. Gluteraldehyde crosslinked bovine collagen (Contigen™) has often been used as an established comparison agent in clinical trials of novel bulking agents, but was removed from the market in 2010.…”
Section: Efficacymentioning
confidence: 99%
“…Gluteraldehyde crosslinked bovine collagen (Contigen™) has often been used as an established comparison agent in clinical trials of novel bulking agents, but was removed from the market in 2010. 8 The efficacy of collagen for SUI has been reported at 48% at 12 months, with a decline to 32% at 34-47 months.…”
Section: Efficacymentioning
confidence: 99%
“…Kullanılan başlıca ajanlar; Politetrafloroetilen, Glutaraldehid çapraz bağlı sığır kollajeni, otolog yağ, slikon, karbon mikroimplant, kalsiyum hidroksilapatit, Etilen vinil . Bu ajanlar ile yapılan müdahalelerin 3 ay gibi kısa sürelerde fayda sağladığı ilerleyen zamanlarda başarılarının azaldığı belirtilmiş-tir 49 . Buna ek olarak ajanların da birbirlerine karşı üstünlüğü olduğu gösterilememiştir 49 .…”
Section: Dbulking Ajanlarunclassified
“…Bu ajanlar ile yapılan müdahalelerin 3 ay gibi kısa sürelerde fayda sağladığı ilerleyen zamanlarda başarılarının azaldığı belirtilmiş-tir 49 . Buna ek olarak ajanların da birbirlerine karşı üstünlüğü olduğu gösterilememiştir 49 .…”
Section: Dbulking Ajanlarunclassified
“…Side effects were rare. A recent Cochrane review by Kirchin et al [74] extensively analyzed what materials would be optimal for bulking injection and how efficacious the bulking agents are. In their review with 14 randomized or quasi-randomized, controlled trials, including 2,004 women, 8 trials compared different agents with collagen among silicone particles, calcium hydroxylapatite, ethylene vinyl alcohol, carbon spheres, and dextranomer hyaluronic acid.…”
Section: Bulking Agentsmentioning
confidence: 99%